ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,064.20
      0.91%
      US Tech 100
      17,197.20
      0.71%
      Dow Jones
      38,225.66
      0.85%
      Brent Oil
      83.91
      0.33%
      Bitcoin
      58,949.30
      -0.29%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Vaxart Inc (VXRT)

      7. Vaxart Inc (VXRT) News

      VXRT

      Vaxart (VXRT)

      Vaxart Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:VXRT
      DateTimeSourceHeadlineSymbolCompany
      2:07PMiHub NewswireFeaturedNanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon
      04/30/20248:00AMGlobeNewswire Inc.Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating MothersNASDAQ:VXRTVaxart Inc
      03/27/20248:00AMGlobeNewswire Inc.Vaxart to Present at World Vaccine Congress Washington 2024 on April 3NASDAQ:VXRTVaxart Inc
      03/20/20248:00AMGlobeNewswire Inc.Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VXRTVaxart Inc
      03/14/20244:01PMGlobeNewswire Inc.Vaxart Provides Business Update and Reports Full Year 2023 Financial ResultsNASDAQ:VXRTVaxart Inc
      03/14/20247:41AMIH Market NewsU.S. Stock Futures Rise Ahead Of PPI and Retail Sales; Oil Prices ClimbNASDAQ:VXRTVaxart Inc
      03/07/20248:00AMGlobeNewswire Inc.Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14NASDAQ:VXRTVaxart Inc
      03/06/20249:23AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VXRTVaxart Inc
      03/06/20248:00AMGlobeNewswire Inc.Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and DirectorNASDAQ:VXRTVaxart Inc
      02/29/20244:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VXRTVaxart Inc
      02/15/20244:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VXRTVaxart Inc
      02/13/20245:16PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VXRTVaxart Inc
      02/05/20248:00AMGlobeNewswire Inc.Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 ChallengeNASDAQ:VXRTVaxart Inc
      02/02/20244:49PMEdgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:VXRTVaxart Inc
      01/19/20245:14PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VXRTVaxart Inc
      01/19/20244:30PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:VXRTVaxart Inc
      01/19/20248:30AMGlobeNewswire Inc.Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine CandidateNASDAQ:VXRTVaxart Inc
      01/16/20245:18PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VXRTVaxart Inc
      01/16/20249:25AMGlobeNewswire Inc.Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital ManagementNASDAQ:VXRTVaxart Inc
      01/16/20249:22AMGlobeNewswire Inc.Vaxart, Inc. Announces Management ChangeNASDAQ:VXRTVaxart Inc
      01/16/20249:19AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VXRTVaxart Inc
      12/21/20238:00AMGlobeNewswire Inc.Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating MothersNASDAQ:VXRTVaxart Inc
      11/02/20234:16PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VXRTVaxart Inc
      11/02/20234:11PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VXRTVaxart Inc
      11/02/20234:01PMGlobeNewswire Inc.Vaxart Provides Business Update and Reports Third Quarter 2023 Financial ResultsNASDAQ:VXRTVaxart Inc
      11/02/20238:00AMGlobeNewswire Inc.Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating MothersNASDAQ:VXRTVaxart Inc
      10/26/20238:00AMGlobeNewswire Inc.Vaxart to Host Third Quarter 2023 Business Update and Financial Results Conference Call on November 2NASDAQ:VXRTVaxart Inc
      10/23/20235:09PMEdgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:VXRTVaxart Inc
      10/23/20235:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VXRTVaxart Inc
      10/11/20238:00AMGlobeNewswire Inc.Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19NASDAQ:VXRTVaxart Inc
       Showing the most relevant articles for your search:NASDAQ:VXRT